In 2015, new tools were developed to modulate fibroblast and macrophage activity to halt liver fibrogenesis and stimulate resolution. Essential factors for resolution were identified and clinical trials yielded potential new antifibrotic drugs. Although innovations were made this year, clinical trials are still hampered by the lack of methods to monitor disease progression.
